Brief: Cognition Therapeutics Announces All Participants Have Completed Their Final Visits
26/11/2024 12:46
Nov 26 (Reuters) - Cognition Therapeutics Inc CGTX.O :
* COGNITION THERAPEUTICS ANNOUNCES ALL PARTICIPANTS HAVE
COMPLETED
THEIR FINAL VISITS IN THE PHASE 2 SHIMMER STUDY OF CT1812 IN
DEMENTIA WITH LEWY BODIES
* COGNITION THERAPEUTICS INC -TOPLINE RESULTS IN SECOND
DEMENTIA
INDICATION EXPECTED TO BE REPORTED IN DECEMBER 2024
Source text: ID:nGNX7N8MYJ
Further company coverage: CGTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cognition Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
U.S. STOCKS ON THE MOVE-CME, Lockheed Martin, Valero Energy
Cognition rises after FDA backs late-stage trial plan for dementia drug
Brief: Cognition Therapeutics Announces Issuance Of Composition Of Matter Patent, Extending Protection For Zervimesine (CT1812) Through 2045
Brief: Cognition Therapeutics Schedules A Type C Meeting With FDA To Align On Endpoints For Phase 3 Trial Of Zervimesine (Ct1812) In DLB